吉西他滨联合卡培他滨二线治疗晚期乳腺癌

Gemcitabin plus capecitabine as a second-line chemotherapy for patients with advanced breast cancer

背景与目的:含蒽环类或紫杉类药物的化疗方案是治疗晚期乳腺癌较佳的方案,但临床有20%～30%的患者疗效不佳,对这部分患者二线化疗目前无统一标准方案。本研究探讨既往接受过蒽环类和紫杉类药物治疗失败的晚期乳腺癌患者,使用吉西他滨联合卡培他滨方案治疗的疗效和毒性。方法:吉西他滨1000mg/m2,静脉滴注,第1、8天;卡培他滨950mg/m2口服,每日2次,第1～14天;每3周为一周期,至少应用2疗程,评价临床疗效和毒性,并进行随访。结果:30例女性患者入本研究,疗效均可评价,CR2例(6.7%),PR12例(40.0%),SD13例(43.3%),PD3例(10.0%),总有效率(CR(PR)46.7%,中位无进展生存期9个月,中位生存期12.5个月。主要毒性是骨髓抑制和手足综合征。结论:吉西他滨联合卡培他滨化疗方案二线治疗晚期乳腺癌有较好疗效,毒性可耐受。

Background and purpose： Chemotherapy including anthracyclin and taxanes is one of the effective regimens for patients with advanced breast cancer, but 20% -30% patients do not achieve a satisfactory curative effect. At present, there is no unified standard second-line chemotherapy regimen for these patients. We studied the efficacy and toxicity of gemcitabin plus capecitabine in the treatment of the patients with advanced breast cancer who had failed in response to the treatment of anthracyclin and taxanes chemotherapy. Methods： Gemcitabin 1 000 mg/m2 iv infusion at dl, 8 and capecitabine 950 mg/m^2 po rid at d1-14. The interval between the two cycles was 3 weeks. The assessment for clinical effect and side effect was conducted for the patients with completion of 2 cycles of chemotherapy at least. Results： 30 female patients were enrolled in this trial , overall response rate was 46.7%, with 6.7% complete response （2/30） and 40% partial response （12/30）. Stable disease was seen in 42.3% （13/30）, and disease progression in 10% （3/30）. Median time to progression was 9 months, and median overall survival was 12.5 months. The main toxicities were myelosuppression and hand-foot syndrome. Conclusions： Gemcitabin plus capecitabine is effective for the patients with advanced breast cancer who failed in the treatment of anthracyclin and taxanes chemotherapy, and its side effect is tolerable.